Olfactory Dysfunction and Brain Health: Clinical Insights, Mechanisms, and Emerging Therapies

Abstract

Olfactory dysfunction, encompassing anosmia, hyposmia, and parosmia, is increasingly recognized not only as a quality-of-life issue but also as a significant marker of neurological and systemic disease. Mounting evidence links olfactory impairment with neurodegenerative disorders, especially Alzheimer's and Parkinson's diseases, suggesting that olfactory testing may offer valuable insights into brain health and preclinical disease states. This review synthesizes current epidemiological data, elucidates the pathophysiological mechanisms underpinning olfactory dysfunction, and discusses clinical features, diagnostic approaches, and management strategies. Recent advances in biomarkers, imaging, and therapeutics are highlighted, alongside guideline-based recommendations to inform clinical practice. A comprehensive understanding of olfactory dysfunction's implications for brain health is essential for clinicians managing at-risk populations.

Introduction

The sense of smell is fundamental to daily living, influencing nutrition, safety, and overall well-being. Olfactory dysfunction, historically underestimated, has gained prominence due to its association with neurodegenerative diseases and its impact on morbidity. Recent research has emphasized the role of olfactory impairment as an early, sometimes prodromal, indicator of neurodegenerative pathology, particularly in Alzheimer's and Parkinson's diseases. The COVID-19 pandemic has further underscored the clinical relevance of smell disorders, as olfactory loss emerged as a hallmark symptom. Understanding the mechanistic, diagnostic, and therapeutic dimensions of olfactory dysfunction is imperative for clinicians to appropriately evaluate and manage affected individuals, especially those at risk for neurological decline.

Epidemiology / Disease Burden

Olfactory dysfunction affects approximately 3–20% of the adult population, with prevalence increasing markedly with age. Epidemiological studies indicate that up to 60% of individuals over 65 experience some degree of olfactory loss. The burden is disproportionately higher in those with chronic rhinosinusitis, head trauma, neurodegenerative diseases, and post-viral syndromes. The COVID-19 pandemic has led to a surge in acute-onset olfactory loss, with estimates suggesting that up to 80% of mild cases experience transient anosmia or hyposmia. The clinical and social consequences include nutritional deficiencies, reduced safety awareness, and psychosocial impacts, such as depression and isolation, highlighting the significant disease burden associated with olfactory impairment.

Pathophysiology

The olfactory system is uniquely vulnerable due to its direct exposure to environmental insults and its neural connections to limbic and cortical brain regions. Olfactory dysfunction may result from peripheral (nasal or olfactory epithelium) or central (olfactory bulb, tract, or cortex) lesions. Peripheral loss often stems from sinonasal inflammation, viral infections, or trauma. Central dysfunction is associated with neurodegenerative pathology: intraneuronal deposition of α-synuclein in Parkinson's disease and amyloid-β or tau in Alzheimer's disease, often beginning in the olfactory bulb and tract. The olfactory epithelium also serves as a potential entry point for neurotropic viruses, including SARS-CoV-2, which may trigger local inflammation, neuronal apoptosis, and subsequent central nervous system involvement.

Risk Factors

Numerous risk factors contribute to olfactory dysfunction. Age is the predominant non-modifiable risk factor. Other significant contributors include male sex, smoking, chronic rhinosinusitis, history of upper respiratory tract infections, traumatic brain injury, and exposure to neurotoxic agents. Genetic predisposition, especially in familial neurodegenerative disease, further increases risk. Comorbidities such as diabetes mellitus, hypertension, and chronic kidney disease have also been implicated. Recent studies have identified viral infections, notably SARS-CoV-2, as acute precipitants of olfactory loss, which in some cases persists long-term.

Clinical Features

Olfactory dysfunction presents as anosmia (complete loss), hyposmia (partial loss), parosmia (distorted perception), or phantosmia (perception of smell in the absence of stimuli). Patients may report diminished flavor perception, poor appetite, and weight loss. In the context of neurodegenerative diseases, olfactory loss often precedes cognitive or motor symptoms by years, serving as a potential biomarker for early disease. Psychiatric symptoms, including depression and anxiety, are common, driven by loss of pleasure in eating, social withdrawal, and safety concerns. Clinical assessment should include a detailed history, focusing on symptom onset, progression, associated neurologic or sinonasal symptoms, and potential exposures.

Diagnosis

Diagnosis of olfactory dysfunction involves a combination of clinical evaluation and objective testing. Bedside identification tests, such as the University of Pennsylvania Smell Identification Test (UPSIT) and Sniffin Sticks, provide quantitative assessment. Neuroimaging, particularly MRI, is indicated when a central cause is suspected, revealing olfactory bulb atrophy or cortical lesions. Further evaluation for underlying neurodegenerative disease may include cognitive screening, dopaminergic imaging, or CSF biomarkers. Laboratory investigations may be warranted to exclude metabolic or infectious etiologies. Accurate diagnosis is critical, as olfactory loss may be the presenting feature of serious underlying pathology.

Treatment & Management

Management of olfactory dysfunction is guided by the underlying etiology. For sinonasal causes, intranasal corticosteroids, saline irrigations, and, in refractory cases, surgery may be effective. Olfactory training repetitive, structured exposure to odors has demonstrated benefit across etiologies, with evidence supporting neural plasticity and functional recovery. Addressing modifiable risk factors, such as smoking cessation and management of comorbidities, is recommended. In neurodegenerative disease, symptomatic treatments are limited, but olfactory loss serves as a prompt for early intervention and cognitive monitoring. Patient education regarding safety, nutrition, and psychosocial support is essential. Adjunctive therapies, such as vitamin A supplementation and omega-3 fatty acids, are under investigation but are not yet standard of care.

Recent Advances / Emerging Therapies

Recent research has focused on regenerative and neuroprotective strategies. Stem cell therapies and intranasal delivery of neurotrophic factors are under preclinical evaluation. Advances in olfactory training protocols, including virtual reality and digital olfactometers, aim to enhance adherence and efficacy. Biomarker discovery using olfactory testing, imaging, and molecular markers is refining risk stratification and early diagnosis in neurodegenerative disease. The COVID-19 pandemic has accelerated research into antiviral and anti-inflammatory agents targeting post-viral olfactory loss. Gene therapy approaches hold promise for congenital anosmia. Despite ongoing challenges, these advances signal a paradigm shift in management and prognosis.

Guideline Recommendations

Professional guidelines advocate for a structured approach to olfactory dysfunction, emphasizing early identification, comprehensive evaluation, and interdisciplinary management. Key recommendations include routine olfactory screening in at-risk populations, especially those over 60 or with family history of neurodegenerative disease. Objective testing should complement clinical history, and neuroimaging considered for unexplained or progressive loss. Olfactory training is recommended as first-line therapy for persistent loss. Referral to neurology or otolaryngology is indicated for atypical or complex cases. Patient counseling regarding safety and nutrition is essential. Ongoing research may soon inform updates to guideline recommendations, particularly concerning biomarker-driven management.

Conclusion

Olfactory dysfunction is a clinically significant and multifaceted disorder with profound implications for brain health. As a sentinel symptom of neurodegeneration and a marker for systemic disease, it demands heightened clinical awareness and a multidisciplinary approach. Advances in diagnostic modalities, therapeutics, and biomarker discovery are poised to transform the landscape of olfactory disorder management. Integrating guideline-based evaluation, evidence-supported therapies, and patient-centered care will enhance outcomes and mitigate the burden of olfactory dysfunction in at-risk populations.